References

1. Kurhanewicz, J., Vigneron, D.B., Hricak, H., et al. (1996). Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7 cm³) spatial resolution. Radiology, 198, 795-805.
2. D'Amico, A. (1996). The role of MR imaging in the selection of therapy for prostate cancer. Magn Reson Imaging Clin N Am, 4, 471-9.
3. Clarke, D.H., Banks, S.J., & Wiederhorn, A.R. (2002). The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants. Int J Rad Onc Biol Phys, 52, 903-10.
4. Roach, M., III, Faillace-Akazawa, P., Malfatti, C., et al. (1996). Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Rad Onc Biol Phys, 35, 1011-8.
5. Kagawa, K., Lee, W.R., Schultheiss, T.E., et al. (1997). Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Rad Onc Biol Phys, 38, 319-25.
6. Reynier, C., Troccaz, J., Fourneret, P., et al. (2004). MRI/TRUS data fusion for prostate brachytherapy. Preliminary results. Med Phys, 31, 1568-75.
7. Wang, L., Hricak, H., Kattan, M.W., et al. (2006). Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology, 238, 597-603.
8. Zakian, K.L., Sircar, K., Hricak, H., et al. (2005). Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology, 234, 804-14.
9. Wetter, A., Hubner, F., Lehnert, T., et al. (2005). Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: Technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol, 15, 645-52.
10. Pickett, B., Vigneault, E., Kurhanewicz, J., et al. (1999). Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J of Rad Onc Biol Phys, 44, 921-9.
11. Pouliot, J., Kim, Y., Lessard, E., et al. (2004). Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Rad Onc Biol Phys, 59, 1196-207.
12. Zaider, M., Zelefsky, M.J., Lee, E.K., et al. (2000). Treatment planning for prostate implants using magnetic-resonance sprectroscopy imaging. Int J Rad Onc Biol Phys, 47, 1085-96.
13. Moerland, M.A., Wijrdeman, H.K., Beersma, R., et al. (1997). Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Rad Onc Biol Phys, 37, 927-33.
14. Dubois, D.F., Prestidge, B.R., Hotchkiss, L.A., et al. (1997). Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. Int J Rad Onc Biol Phys, 39, 1037-41.
15. Polo, A., Cattani, F., Vavassori, A., et al. (2004). MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Rad Onc Biol Phys, 60, 1572-9.
16. Chan, T.W., & Kressel, H.Y. (1991). Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging, 1, 503-11.
17. Pickett, B., Ten Haken, R.K., & Kurhanewicz, J., et al. (2004). Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Rad Onc Biol Phys, 59, 665-73.
18. Pucar, D., Shukla-Dave, A., Hricak, H., et al. (2005). Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology, 236, 545-53.
19. Shukla-Dave, A., Hricak, H., Eberhardt, S.C., et al. (2004). Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology, 231, 717-24.